Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ribociclib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 known ✓ | P11802 | 14/20 | 1.00 |
| ▸ | CDK6 known ✓ | Q00534 | 4/20 | 1.00 |
| ▸ | CCND1 | P24385 | 8/20 | 1.00 |
| ▸ | CDK2 | P24941 | 3/20 | 1.00 |
| ▸ | CCND3 | P30281 | 2/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | CCNT1 | O60563 | 1/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 1/20 | 1.00 |
| ▸ | FECH | P22830 | 1/20 | 1.00 |
| ▸ | CDK9 | P50750 | 1/20 | 1.00 |
| ▸ | CDK16 | Q00536 | 1/20 | 1.00 |
| ▸ | MAP3K1 | Q13233 | 1/20 | 1.00 |
| ▸ | CAMK2G | Q13555 | 1/20 | 1.00 |
| ▸ | CAMK2D | Q13557 | 1/20 | 1.00 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 1.00 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 1.00 |
| ▸ | SIK2 | Q9H0K1 | 1/20 | 1.00 |
| ▸ | CDK1 | P06493 | 3/20 | 0.95 |
| ▸ | CCND2 | P30279 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ribociclib SCHEMBL29912679 | 1.00 | CDK4 (1.00) | CDK4CCND1CDK6CDK2CCND3 | |
| Ribociclib SCHEMBL302310 | 1.00 | CDK4 (1.00) | CDK4CCND1CDK6CDK2CCND3 | |
| Ribociclib SCHEMBL29384231 | 1.00 | CDK4 (1.00) | CDK4CCND1CDK6CDK2CCND3 | |
| Ribociclib SCHEMBL29390270 | 0.99 | CDK4 (0.98) | CDK4CCND1CDK6CDK2CCND3 | |
| Ribociclib SCHEMBL1998188 | 0.99 | CDK4 (0.98) | CDK4CCND1CDK6CDK2CCND3 | |
| SCHEMBL31607940 | 0.98 | CDK4 (0.97) | CDK4CCND1CDK6CDK2CCND3 | |
| SCHEMBL1993460 | 0.98 | CDK2 (1.00) | CDK4CCND1CDK6CDK2CCND3 | |
| Ribociclib SCHEMBL29414075 | 0.95 | CDK4 (0.91) | CDK4CCND1CDK6CDK2CCND3 | |
| Ribociclib SCHEMBL2684999 | 0.95 | CDK4 (0.91) | CDK4CCND1CDK6CDK2CCND3 | |
| SCHEMBL31607869 | 0.95 | CDK4 (0.91) | CDK4CCND1CDK6CDK2CCND3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 201 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3923941-B1 | PHARMACEUTICAL COMBINATION COMPRISING TNO155 AND RIBOCICLIB | NOVARTIS AG (CH) | 2025-12-03 | — | — | EP | claimed |
| US-12343344-B2 | Pharmaceutical combination comprising TNO155 and ribociclib | NOVARTIS AG (CH) | 2025-07-01 | — | — | US | claimed |
| EP-4561704-A2 | USE OF GLYCOGEN METABOLISM INHIBITORS FOR THE TREATMENT OF CANCER | The University Of Vermont (US) | 2025-06-04 | — | — | EP | claimed |
| EP-4333847-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF MPNST | Novartis AG (CH) | 2024-03-13 | — | — | EP | claimed |
| WO-2024026458-A2 | USE OF GLYCOGEN METABOLISM INHIBITORS FOR THE TREATMENT OF CANCER | THE UNIVERSITY OF VERMONT (US) | 2024-02-01 | — | — | WO | claimed |
| CN-117177752-A | Compounds and compositions for the treatment of MPNST | 诺华股份有限公司 | 2023-12-05 | — | — | CN | claimed |
| EP-4259659-A1 | METHODS OF INDUCING AN IMMUNOMODULATORY TUMOR RESPONSE | Cornell University (US) | 2023-10-18 | — | — | EP | claimed |
| EP-3595725-B1 | COMBINATION THERAPIES FOR THE TREATMENT OF BREAST CANCER | EISAI R&D MAN CO LTD (JP) | 2023-05-03 | — | — | EP | claimed |
| EP-4126244-A1 | COMBINATION OF ANTI-HER2 ANTIBODY AND CDK INHIBITIOR FOR TUMOR TREATMENT | Jiangsu Alphamab Biopharmaceuticals Co., Ltd. (CN) | 2023-02-08 | — | — | EP | claimed |
| CN-115666574-A | Combination of | 里科瑞尔姆IP控股有限责任公司 | 2023-01-31 | — | — | CN | claimed |
| EP-4110344-A2 | USE OF THYROMIMETICS FOR THE TREATMENT OF CANCER | The University Of Vermont (US) | 2023-01-04 | — | — | EP | claimed |
| EP-4106760-A1 | COMBINATIONS | Recurium IP Holdings, LLC (US) | 2022-12-28 | — | — | EP | claimed |
| WO-2022234409-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF MPNST | NOVARTIS AG (CH) | 2022-11-10 | — | — | WO | claimed |
| US-11439646-B2 | Anti-proliferative agents for treating PAH | PFIZER INC. (US) | 2022-09-13 | — | — | US | claimed |
| WO-2022125652-A1 | METHODS OF INDUCING AN IMMUNOMODULATORY TUMOR RESPONSE | CORNELL UNIVERSITY (US) | 2022-06-16 | — | — | WO | claimed |
| WO-2026090174-A1 | COMPOSITIONS FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS AND METHODS FOR THE SYNTHESIS AND USE THEREOF | BRYET US, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-4731793-A2 | COMPOSITIONS COMPRISING ANTINEOPLASTONS AND METHODS OF TREATING PANCREATIC CANCER | Burzynski, Stanislaw R. (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-3972651-A2 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | Novartis AG (CH) | 2022-03-30 | — | — | EP | disclosed |
| US-11286259-B2 | Co-crystals of ribociclib and co-crystals of ribociclib monosuccinate, preparation method therefor, compositions thereof, and uses thereof | HANGZHOU SOLIPHARMA CO., LTD. (CN) | 2022-03-29 | — | — | US | disclosed |
| WO-2022029798-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING RIBOCICLIB | NATCO PHARMA LIMITED (IN) | 2022-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11286259-B2 | Co-crystals of ribociclib and co-crystals of ribociclib monosuccinate, preparation method therefor, compositions thereof, and uses thereof | COASY, RRBP1, ATIC | CDK4 771/4885CDK6 276/4885CCND1 1946/4885 |
| US-11439646-B2 | Anti-proliferative agents for treating PAH | CDK8, CDK4, CDKL1 | CDK4 2/4885CDK6 9/4885CCND1 55/4885 |
| US-12343344-B2 | Pharmaceutical combination comprising TNO155 and ribociclib | CDK4, CDK6, RB1 | CDK4 1/4885CDK6 2/4885CCND1 283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.